What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Insitro
Combines machine learning and high-throughput biology to transform drug discovery.
What they do
insitro combines machine learning and high-throughput biology for drug discovery. Its October 15, 2026 AstraZeneca collaboration covers MASH and cardiomyopathies, with $40M upfront, up to approximately $1.46B in contingent milestones and potential single-digit royalties. These payments are partnership consideration, not equity funding.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- South San Francisco, USA
- Region
- North America
- Founded
- 2018
- Total funding
- $743M raised
Notable investors: Andreessen Horowitz, Canada Pension Plan Investment Board, ARCH Venture Partners, Foresite Capital.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA